The legislation would require drugmakers to give the state a 60-day notice before raising the price of a drug more than 10 percent, among other regulations for branded drugmakers. The bill’s opponents argue the regulations will place a burden on generic competition and cause the price of generic drugs to increase.
Market Probe, which conducted the survey on behalf of AAM, polled more than 1,000 California residents about the drug price bill earlier this month. Sixty-six percent of respondents were unwilling to support the bill, saying it will harm patients who rely on cheaper generic drugs.
“Despite the perception that consumers support this legislation, voters are rightfully concerned about how it will impact their healthcare — and their wallet,” said Carrie Hartgen, AAM’s vice president of state government affairs, in an emailed release. “Any new requirements must protect the ability of generics to effectively compete in the marketplace and continue to drive down health care costs in California.”
More articles on supply chain:
Samsung widens stake in prescription drug market through partnership with Japanese pharmaceutical company
Patients brace for price of ‘breakthrough’ leukemia drug CTL019
Bella Pharmaceuticals voluntarily recalls all lots of unexpired sterile drug products
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.